Cargando…

Staging Disease Severity Using the Alzheimer’s Disease Composite Score (ADCOMS): A Retrospective Data Analysis

INTRODUCTION: The Alzheimer’s disease (AD) composite score (ADCOMS) has been shown to be a more sensitive measure of cognitive change in early AD (i.e., mild cognitive impairment [MCI] and mild AD) than commonly used measures. This study derived ADCOMS value ranges associated with different disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tahami Monfared, Amir Abbas, Houghton, Katherine, Zhang, Quanwu, Mauskopf, Josephine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857364/ https://www.ncbi.nlm.nih.gov/pubmed/35099758 http://dx.doi.org/10.1007/s40120-022-00326-y

Ejemplares similares

Correction to: Staging Disease Severity Using the Alzheimer’s Disease Composite Score (ADCOMS): A Retrospective Data Analysis
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Assessing the Clinical Meaningfulness of the Alzheimer’s Disease Composite Score (ADCOMS) Tool
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

A Systematic Review of Clinical Practice Guidelines for Alzheimer’s Disease and Strategies for Future Advancements
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
por: Wang, Jinping, et al.
Publicado: (2016)

Alzheimer’s Disease: Epidemiology and Clinical Progression
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

The Humanistic and Economic Burden of Alzheimer's Disease
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

The Potential Economic Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Understanding Barriers Along the Patient Journey in Alzheimer’s Disease Using Social Media Data
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Clinical Staging of Alzheimer’s Disease: Concordance of Subjective and Objective Assessments in the Veteran’s Affairs Healthcare System
por: Morin, Peter, et al.
Publicado: (2022)

Clinical and Scientific Challenges to Effectiveness Studies Under Coverage with Evidence Development in Alzheimer’s Disease
por: Morin, Peter J., et al.
Publicado: (2023)

A Path to Improved Alzheimer’s Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer’s Disease from the CLARITY AD Trial
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

Estimated Societal Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

Factors Driving the Transition of Alzheimer’s Disease Patients to Institutional Long-term Care
por: Davila, Heather, et al.
Publicado: (2021)

Treatment Preference for Alzheimer’s Disease: A Multicriteria Decision Analysis with Caregivers, Neurologists, and Payors
por: Dranitsaris, George, et al.
Publicado: (2022)

Therapeutic preference for Alzheimer’s disease treatments: a discrete choice experiment with caregivers and neurologists
por: Dranitsaris, George, et al.
Publicado: (2023)

Estimating Transition Probabilities Across the Alzheimer’s Disease Continuum Using a Nationally Representative Real-World Database in the United States
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation
por: Igarashi, Ataru, et al.
Publicado: (2023)

Rule-Based Identification of Individuals with Mild Cognitive Impairment or Alzheimer’s Disease Using Clinical Notes from the United States Veterans Affairs Healthcare System
por: Aguilar, Byron J., et al.
Publicado: (2023)

Burden of Disease and Current Management of Dementia with Lewy Bodies: A Literature Review
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2019)

Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
por: Quon, Peter L., et al.
Publicado: (2019)

Comparison of the effect of lemborexant and other insomnia treatments on driving performance: a systematic review and meta-analysis
por: McElroy, Heather, et al.
Publicado: (2021)

Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis
por: McElroy, Heather, et al.
Publicado: (2021)

Evaluating Vaccination Programs That Prevent Diseases With Potentially Catastrophic Health Outcomes: How Can We Capture the Value of Risk Reduction?
por: Mauskopf, Josephine, et al.
Publicado: (2021)

Cognitive composite score association with Alzheimer’s disease plaque and tangle pathology
por: Malek-Ahmadi, Michael, et al.
Publicado: (2018)

Composite cognitive and functional measures for early stage Alzheimer's disease trials
por: Schneider, Lon S., et al.
Publicado: (2020)

Treatment Options for Dementia with Lewy Bodies: A Network Meta-Analysis of Randomised Control Trials
por: Tahami Monfared, Amir A., et al.
Publicado: (2020)

Commentary on Composite cognitive and functional measures for early stage Alzheimer's disease trials
por: Rentz, Dorene M., et al.
Publicado: (2020)

Commentary: Composite cognitive and functional measures for early stage Alzheimer's disease trials
por: Harrison, John E.
Publicado: (2020)

Quantifying cognitive resilience in Alzheimer’s Disease: The Alzheimer’s Disease Cognitive Resilience Score
por: Yao, Tianyi, et al.
Publicado: (2020)

Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score
por: Lim, Yen Ying, et al.
Publicado: (2015)

In vivo tau staging in Alzheimer’s disease
por: Therriault, Joseph, et al.
Publicado: (2022)

The Model for End-Stage Liver Disease-Sodium Score at Admission Is Prognostic of Covid-19 Disease Severity
por: Wagner, Jason, et al.
Publicado: (2020)

Response to Schneider and Goldberg “Composite cognitive and functional measures for early stage Alzheimer's disease trials”
por: Sano, Mary, et al.
Publicado: (2020)

Response to peer commentaries: Composite cognitive and functional measures for early stage Alzheimer's disease trials
por: Schneider, Lon S., et al.
Publicado: (2020)

Enriching the design of Alzheimer's disease clinical trials: Application of the polygenic hazard score and composite outcome measures
por: Banks, Sarah J., et al.
Publicado: (2020)

Polygenic resilience score may be sensitive to preclinical Alzheimer’s disease changes
por: Eissman, Jaclyn M., et al.
Publicado: (2023)

Association of CALHM1 Gene Polymorphism with Late Onset Alzheimer's Disease in Iranian Population
por: Aqdam, Meysam Jafari, et al.
Publicado: (2010)

Cell-type-specific Alzheimer’s disease polygenic risk scores are associated with distinct disease processes in Alzheimer’s disease
por: Yang, Hyun-Sik, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1rl2qdkcpk9d4hsht9m1ln5p8k